Curcumin (turmeric)

What this is

Native curcumin absorption <1% — rapidly conjugated to glucuronide/sulfate and excreted. **The formulation paradox is the central biohacker decision input**: bioavailability-enhanced forms (Meriva/phytosome; Theracurmin; BCM-95; NovaSol; piperine-boosted) deliver 5-30x higher plasma curcumin, but hepatotoxicity case reports are CONCENTRATED in exactly these formulations. EFSA, Italian Phytovigilance, DILIN, and Icelandic case clusters all point the same direction — bioavailability-enhanced products at standard supplement doses produce occasional idiosyncratic cholestatic hepatitis. EFSA's 180 mg/day ADI is below typical biohacker dosing. Italian Ministry of Health required new warning labels on Curcuma longa supplements 2024-2025. **OA paradox**: 2025 network MA on knee OA (17 studies) found conventional curcuminoid preparations had numerically LARGER WOMAC pain reduction (-3.17) than bioavailability-enhanced ones (-2.47) — complicates the "phytosomal is better" supplement-industry narrative. NAFLD/MASLD is the strongest specific indication for phytosomal curcumin per the 2025 ALT/AST pooled MA. **Practical read of 2024-2025 evidence**: (a) prefer conventional curcuminoids at moderate doses with food/fat; (b) stay below the EFSA ADI of ~3 mg/kg/day; (c) monitor LFTs if using bioavailability-enhanced forms long-term; (d) hold immediately if jaundice/dark urine/RUQ pain. Phytosomal/Meriva remains reasonable for NAFLD-targeted use under monitoring; for general anti-inflammatory or OA use, conventional is now better-justified.

Mechanism

Diferuloylmethane polyphenol from Curcuma longa; pleiotropic effects — NF-κB; COX-2; 5-LOX; JAK-STAT; Nrf2 inhibition/activation across dozens of pathways; native curcumin has <1% oral bioavailability and is rapidly conjugated/excreted; formulation strategies (phytosome, micelle, nanoemulsion, piperine co-administration) raise plasma exposure 5-30x

Dose & route

500-2000 mg/day standardized curcuminoids; formulation matters — native (<1% absorption); piperine 5-20 mg co-admin (~20x); phytosome/Meriva (~20-29x AUC); BCM-95 (~7x); Theracurmin (~27x AUC and ~5.6x Cmax vs Meriva); NovaSol micelle (very high Cmax with rapid decline)

Citations

• https://pubmed.ncbi.nlm.nih.gov/27533649/
• https://pubmed.ncbi.nlm.nih.gov/29480523/
• https://pmc.ncbi.nlm.nih.gov/articles/PMC6770259/
• https://pmc.ncbi.nlm.nih.gov/articles/PMC10061533/
• https://pmc.ncbi.nlm.nih.gov/articles/PMC11850025/
• https://pmc.ncbi.nlm.nih.gov/articles/PMC12309109/
• https://pubmed.ncbi.nlm.nih.gov/41599857/
• https://pubmed.ncbi.nlm.nih.gov/41978084/

Links go to the source. If a link is dead or you want something re-checked, let me know.